First Horizon Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

First Horizon Advisors’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$10K	Hold	156	–	–	﹤0.01%	1680
2025 Q1	$9.91K	Hold	156	–	–	﹤0.01%	1599
2024 Q4	$10.4K	Hold	156	–	–	﹤0.01%	1586
2024 Q3	$10.9K	Hold	156	–	–	﹤0.01%	1576
2024 Q2	$10.1K	Hold	156	–	–	﹤0.01%	1528
2024 Q1	$10.1K	Hold	156	–	–	﹤0.01%	1573
2023 Q4	$10.3K	Hold	156	–	–	﹤0.01%	1586
2023 Q3	$8.9K	Hold	156	–	–	﹤0.01%	1557
2023 Q2	$9.56K	Hold	156	–	–	﹤0.01%	1562
2023 Q1	$9.79K	Hold	156	–	–	﹤0.01%	1568
2022 Q4	$9.9K	Hold	156	–	–	﹤0.01%	1564
2022 Q3	$9K	Hold	156	–	–	﹤0.01%	1560
2022 Q2	$9K	Buy	+156	New	+$8.99K	﹤0.01%	1632
2022 Q1	–	Sell	-156	Closed	-$11K	–	2135
2021 Q4	$11K	Hold	156	–	–	﹤0.01%	1489
2021 Q3	$11K	Hold	156	–	–	﹤0.01%	1502
2021 Q2	$12K	Hold	156	–	–	﹤0.01%	1293
2021 Q1	$11K	Hold	156	–	–	﹤0.01%	1263
2020 Q4	$10K	Buy	+156	New	+$9.88K	﹤0.01%	1075

Other funds holding PBE

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

First Horizon Advisors's PBE Position: Q2 2025 in Review

First Horizon Advisors held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q2 2025 at 156 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1680.

First Horizon Advisors first reported a position in PBE in Q4 2020 and has held it in 18 quarters since. The position peaked at $12K in Q2 2021. 94 funds tracked by Wall St. Rank hold PBE as of Q2 2025.

First Horizon Advisors held 156 shares of Invesco Biotechnology & Genome ETF worth $10K as of Q2 2025.
First Horizon Advisors left its Invesco Biotechnology & Genome ETF share count unchanged in Q2 2025.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1680 holding.
First Horizon Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q4 2020 and has held it in 18 quarters since.
First Horizon Advisors's Invesco Biotechnology & Genome ETF position peaked at $12K in Q2 2021.
94 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.